search
Back to results

Primary Chemoprevention of Familial Adenomatous Polyposis With Berberine Hydrochloride

Primary Purpose

Colorectal Adenomas

Status
Completed
Phase
Phase 2
Locations
China
Study Type
Interventional
Intervention
100mg Berberine hydrochloride
300mg Berberine hydrochloride
Placebo Oral Tablet
Sponsored by
Xijing Hospital of Digestive Diseases
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Colorectal Adenomas

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients aged 18-65 years
  • Patients with familial adenomatous polyposis, who had not had their entire colorectum removed, and who had five or more polyps 2 mm or more in diameter that could be assessed endoscopically
  • All potential subjects received genetic counseling before undergoing genetic testing for APC gene mutations.
  • Eligible subjects had a disease-causing mutation of the APC gene but had no endoscopically detectable colorectal adenomatous polyps and no history of colonic surgery

Exclusion Criteria:

  • Patients who are hypersensitive or intolerant to the drugs
  • Patients who had a history of colectomy or colectomy anticipated within 8 months after randomization
  • Patients with abnormal results of serum laboratory tests (a white-cell count of less than 4000 per cubic millimeter, a platelet count of less than 100,000 per cubic millimeter, a blood urea nitrogen level of more than 25 mg per deciliter (8.9 mmol per liter), a serum creatinine level of more than 1.5 mg per deciliter (132.6 µmol per liter))
  • Patients with diabetes mellitus, severe renal disease or cardiovascular disease (defined by a New York Heart Association functional classof III or IV)
  • Patients with hypercalcemia or urolithiasis
  • Patients with hemolytic anemia and glucose -6- phosphate dehydrogenase deficiency
  • Patients had clinically obvious narcotic or alcohol dependence during the previous 6 months
  • Patients had used NSAIDs including aspirin at any dose on 3 or more days per month during each of the 3 months before enrollment or for a period of 36 days in the previous year; or had a history of stroke, transient ischemic attacks, angina, myocardial infarction, or atherosclerotic peripheral vascular disease
  • Pregnant women, women during breast-feeding period, or women with expect pregnancy
  • Patients with a history of subtotal gastrectomy or partial bowel resection
  • Patients who are not able to cooperate
  • Individual who are involved in designing, planning or performing this clinical trial
  • Patients with medical conditions who are not appropriate to participate the study
  • Patients with any condition that could be worsened by supplemental Berberine hydrochloride

Sites / Locations

  • Li

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Placebo Comparator

Arm Label

100mg Berberine hydrochloride group

300mg Berberine hydrochloride group

Placebo oral tablets

Arm Description

Berberine hydrochloride 100mg tablet by mouth, two times per day for 6 months

Berberine hydrochloride 300mg tablet by mouth, two times per day for 6 months

identical-appearing placebo tablets by mouth, two times per day for 6 months

Outcomes

Primary Outcome Measures

Cumulative the numbers and diameters of those colorectal adenomas during Berberine hydrochloride or placebo treatment in patients with familial adenomatous polyposis
The primary objective of this study is to investigate the number and diameters of colorectal polyps after Berberine hydrochloride or placebo intervention. To ascertain that the same area was scored at base line and at month 6, polyps were counted in pairs of photographs. One investigator, other than the endoscopist, who did not know the treatment, performed the scoring. Videotapes were used to resolve ambiguities and confirm polyp counts. The diameter of those colorectal adenomas was measured in millimeters with a graduated scale passed through the colonoscopy biopsy channel.

Secondary Outcome Measures

Full Information

First Posted
November 2, 2017
Last Updated
July 24, 2022
Sponsor
Xijing Hospital of Digestive Diseases
search

1. Study Identification

Unique Protocol Identification Number
NCT03333265
Brief Title
Primary Chemoprevention of Familial Adenomatous Polyposis With Berberine Hydrochloride
Official Title
The Effect of Berberine Hydrochloride in Familial Adenomatous Polyposis:a Prospective, Randomized, Double Blind, Placebo-controlled, Multicenter Clinical Trial
Study Type
Interventional

2. Study Status

Record Verification Date
July 2022
Overall Recruitment Status
Completed
Study Start Date
September 1, 2017 (Actual)
Primary Completion Date
August 31, 2020 (Actual)
Study Completion Date
June 1, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Xijing Hospital of Digestive Diseases

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
In recent years, Berberine hydrochloride has been reported to inhibit cancer cell proliferation and to be cytotoxic towards cancer cells. Patients with familial adenomatous polyposis have a nearly 100 percent risk of colorectal cancer. The aim of this study is to investigate the chemopreventive effects Berberine hydrochlorid on the regression of colorectal adenomas.
Detailed Description
Familial adenomatous polyposis is an autosomal dominant syndrome caused by a germ-line mutation of the adenomatous polyposis coli (APC) gene located at chromosome 5q21. The disorder is characterized by the development of hundreds of colorectal adenomas during adolescence. Colorectal cancer will develop in nearly all affected persons by the sixth decade of life if prophylactic colectomy is not performed. Because the adenoma-to-carcinoma sequence in familial adenomatous polyposis resembles sporadic colon carcinogenesis, studies of familial adenomatous polyposis may contribute to the prevention of sporadic adenomas and colon cancer. BBR, an isoquinoline alkaloid, is a natural compound in numerous Chinese herb plants such as Berberisaristata, Coptischinensis, Coptis rhizome, etc. In recent years, Berberine hydrochloride has been reported to inhibit cancer cell proliferation and to be cytotoxic towards cancer cells. The aim of this study is to investigate the regression effect of Berberine hydrochloride on the colorectal adenomas in patients with familial adenomatous polyposis.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Colorectal Adenomas

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 2, Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
100 (Actual)

8. Arms, Groups, and Interventions

Arm Title
100mg Berberine hydrochloride group
Arm Type
Experimental
Arm Description
Berberine hydrochloride 100mg tablet by mouth, two times per day for 6 months
Arm Title
300mg Berberine hydrochloride group
Arm Type
Experimental
Arm Description
Berberine hydrochloride 300mg tablet by mouth, two times per day for 6 months
Arm Title
Placebo oral tablets
Arm Type
Placebo Comparator
Arm Description
identical-appearing placebo tablets by mouth, two times per day for 6 months
Intervention Type
Drug
Intervention Name(s)
100mg Berberine hydrochloride
Other Intervention Name(s)
100mg Berberine hydrochloride tablet ("Sine Tianping")
Intervention Description
patients take the Berberine hydrochloride 100mg tablet by mouth, 2 times a day with 6 months
Intervention Type
Drug
Intervention Name(s)
300mg Berberine hydrochloride
Other Intervention Name(s)
300mg Berberine hydrochloride tablet ("Sine Tianping")
Intervention Description
patients take the Berberine hydrochloride 300mg tablet by mouth, 2 times a day with 6 months
Intervention Type
Drug
Intervention Name(s)
Placebo Oral Tablet
Other Intervention Name(s)
Placebo (for Berberine hydrochloride)
Intervention Description
patients take mmic Berberine hydrochloride tablet by mouth, 2 times a day with 6 months
Primary Outcome Measure Information:
Title
Cumulative the numbers and diameters of those colorectal adenomas during Berberine hydrochloride or placebo treatment in patients with familial adenomatous polyposis
Description
The primary objective of this study is to investigate the number and diameters of colorectal polyps after Berberine hydrochloride or placebo intervention. To ascertain that the same area was scored at base line and at month 6, polyps were counted in pairs of photographs. One investigator, other than the endoscopist, who did not know the treatment, performed the scoring. Videotapes were used to resolve ambiguities and confirm polyp counts. The diameter of those colorectal adenomas was measured in millimeters with a graduated scale passed through the colonoscopy biopsy channel.
Time Frame
From baseline to 6 months.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients aged 18-65 years Patients with familial adenomatous polyposis, who had not had their entire colorectum removed, and who had five or more polyps 2 mm or more in diameter that could be assessed endoscopically All potential subjects received genetic counseling before undergoing genetic testing for APC gene mutations. Eligible subjects had a disease-causing mutation of the APC gene but had no endoscopically detectable colorectal adenomatous polyps and no history of colonic surgery Exclusion Criteria: Patients who are hypersensitive or intolerant to the drugs Patients who had a history of colectomy or colectomy anticipated within 8 months after randomization Patients with abnormal results of serum laboratory tests (a white-cell count of less than 4000 per cubic millimeter, a platelet count of less than 100,000 per cubic millimeter, a blood urea nitrogen level of more than 25 mg per deciliter (8.9 mmol per liter), a serum creatinine level of more than 1.5 mg per deciliter (132.6 µmol per liter)) Patients with diabetes mellitus, severe renal disease or cardiovascular disease (defined by a New York Heart Association functional classof III or IV) Patients with hypercalcemia or urolithiasis Patients with hemolytic anemia and glucose -6- phosphate dehydrogenase deficiency Patients had clinically obvious narcotic or alcohol dependence during the previous 6 months Patients had used NSAIDs including aspirin at any dose on 3 or more days per month during each of the 3 months before enrollment or for a period of 36 days in the previous year; or had a history of stroke, transient ischemic attacks, angina, myocardial infarction, or atherosclerotic peripheral vascular disease Pregnant women, women during breast-feeding period, or women with expect pregnancy Patients with a history of subtotal gastrectomy or partial bowel resection Patients who are not able to cooperate Individual who are involved in designing, planning or performing this clinical trial Patients with medical conditions who are not appropriate to participate the study Patients with any condition that could be worsened by supplemental Berberine hydrochloride
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Weizhong Wang, MD,PH.D
Organizational Affiliation
Xijing digestive surgery center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Li
City
Xi'an
State/Province
Shaanxi
ZIP/Postal Code
710000
Country
China

12. IPD Sharing Statement

Learn more about this trial

Primary Chemoprevention of Familial Adenomatous Polyposis With Berberine Hydrochloride

We'll reach out to this number within 24 hrs